Oncogene

CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma

Retrieved on: 
Monday, December 12, 2022
R.J. Corman Railroad Group, Oncology, Hematology, Serum, CBP, Internal medicine, PR, Multiple myeloma, Drug discovery, Society, Endpoint security, Mayo Clinic College of Medicine and Science, Patient, DNA, Mayo Clinic, University of Cambridge, Cancer, Dana–Farber Cancer Institute, Oncogene, Research, Gurdon Institute, Partial-response maximum-likelihood, Takeda Pharmaceutical Company, Division, Disease, NHS foundation trust, MCRPC, Dexamethasone, RRMM, MYC, The Christie NHS Foundation Trust, Lymphatic system, Translation, University, IRF4, University of Manchester, Harvard Medical School, Gene, Toxic leukoencephalopathy, ASH, Cancer research, Medical imaging, Pharmaceutical industry, Medicine

Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."

Key Points: 
  • Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."
  • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
    CellCentric has developed inobrodib from concept through to clinical trials.
  • It is an oral, first in class small molecule inhibitor drug that targets twin cancer gene regulators p300 and CBP.
  • The company actively pursued multiple drug discovery programmes before prioritising p300/CBP inhibition and inobrodib.

Rain Therapeutics Provides Interim Analysis of Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)

Retrieved on: 
Friday, November 4, 2022
Private Securities Litigation Reform Act, Progression-free survival, RECIST, Therapy, LPS, Oncogene, CN, Histology, Food, PRS, Corporation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, EGFR, FDA, Safety, KRAS, Neoplasm, CDKN2A, COVID-19, Genetics, RAD52, PIK3CA, MANTRA, Nasdaq, U.S. Securities and Exchange Commission, Clinical trial, Data, MDM2, Cancer, Health, Liposarcoma, Security (finance), RAIN, Bachelor of Medicine, Bachelor of Surgery, Patient, Biliary tract, Pharmaceutical industry, Medical imaging

NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead clinical candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced preliminary data in the multicenter, single arm, open-label, Phase 2 basket trial evaluating milademetan, an oral mouse double minute 2 (MDM2) inhibitor, for the treatment of MDM2-amplified advanced solid tumors.

Key Points: 
  • We are encouraged by the preliminary observations from the MANTRA-2 trial, said Avanish Vellanki, co-founder and chief executive officer of Rain.
  • In addition, anti-tumor activity was observed in patients with genetic co-alterations, and in tumors with MDM2 copy number above 8.
  • Hence, we plan to revise the protocol to include patients tested locally for MDM2 copy number of 8 and greater.
  • Rain has completed enrollment in a Phase 3 trial of milademetan (MANTRA) in patients with LPS, and is evaluating milademetan in a Phase 2 tumor-agnostic basket trial in certain solid tumors (MANTRA-2).

BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative Symposium

Retrieved on: 
Monday, October 17, 2022
LinkedIn, Lists of diseases, Lung, PALO, U.S. Securities and Exchange Commission, Drug Quality and Security Act, SEC, Webcast, AKT, Securities Exchange Act of 1934, Fourth, Hope, Science, PIK3CA, Neoplasm, Patient, Twitter, Annual report, RAF, HER, RAS, Securities Act of 1933, Nasdaq, KRAS, Cancer, Oncogene, Form 10-K, Hyperglycemia, RTK, NSCLC, GDP, Breast, Exchange, GLOBE, Environment, Mall of America, GTP, Calendar, FDA, COVID-19, Lead, Risk, Pharmaceutical industry, Medical imaging, MD

BridgeBio will also be hosting an investor call at 1:30 ET today to discuss the data.

Key Points: 
  • BridgeBio will also be hosting an investor call at 1:30 ET today to discuss the data.
  • BridgeBio has selected a next-generation KRASG12C dual inhibitor development candidate, BBO-8520, and plans to enter the clinic in 2023.
  • BBO-8520 is the first-known small molecule that directly binds and inhibits KRASG12C in both its active (GTP bound) and inactive (GDP bound) conformations.
  • Inhibiting PI3K activity by preventing its interaction with RAS can provide a tumor selective mechanism that spares glucose metabolism.

BMF-219 Enters the Clinic for KRAS Solid Tumors

Retrieved on: 
Friday, October 14, 2022
U.S. Securities and Exchange Commission, Colon, Pancreatic cancer, PDAC, Drug Quality and Security Act, Risk, SEC, Securities Exchange Act of 1934, IND, Lists of diseases, SEER, Patient, Research, Investigational New Drug, Securities Act of 1933, CRC, Cancer, RAS, Nasdaq, Colorectal cancer, KRAS, Oncogene, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Lung cancer, Mutation, Rectum, Phosphorylation, TEAM, Osteopathic medicine in Canada, Board, Incidence, Safety, Prognosis, Diabetes, Survival, GLOBE, NCI, FDA, Consultant, Fusion, Pharmaceutical industry, Medical imaging, Vaccine, NSCLC

Biomea Fusion announces FDA clearance of Investigational New Drug (IND) application for covalent menin inhibitor BMF-219 in KRAS solid tumors.

Key Points: 
  • Biomea Fusion announces FDA clearance of Investigational New Drug (IND) application for covalent menin inhibitor BMF-219 in KRAS solid tumors.
  • BMF-219 is the first menin inhibitor to enter clinical trials for the treatment of solid tumors.
  • KRAS is the most frequently mutated isoform amongst RAS oncogenes in human solid tumors, with high prevalence in NSCLC, CRC, and pancreatic cancer.
  • With only one approved therapy targeting KRAS G12C for locally advanced or metastatic NSCLC, KRAS-driven tumors continue to represent a significant unmet medical need.

AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

Retrieved on: 
Tuesday, October 11, 2022
Research, Genetics, Clinical Trials, Stem Cells, Biotechnology, Other Health, Health, Science, Oncology, LinkedIn, Data collection, Observation, AVRO, HSPC, Machine learning, Institute, European Society of Gene and Cell Therapy, EF1, Health, EFS, Stem cell, Cystinosis, Gaucher, Phrase, SAGA, Gene, HSC, IVIM, Compte rendu, Cell, Twitter, Cancer, Private Securities Litigation Reform Act, Industry, Clinical trial, Central nervous system, MECOM, ESGCT, Oncogene, Risk, Glycogen storage disease type II, Hospital, Growth, Hannover Medical School, Research, Division, Security (finance), Hunter syndrome, Lists of diseases, U.S. Securities and Exchange Commission, Algorithm, Gene expression, Experimental Hematology, Patient, Harvard Medical School, Nasdaq, MND, Safety, COVID-19, Molecular Therapy, Pharmaceutical industry, Vaccine

In collaboration with Professor Axel Schambach, Ph.D., Institute of Experimental Hematology, Hannover Medical School, Germany, AVROBIO is pioneering the use of two advanced preclinical cell-based assays -- in vitro immortalization (IVIM) assay and the novel surrogate assay for genotoxicity assessment (SAGA) -- to evaluate viral vectors before they move into clinical programs. Together these assays are designed to assess which vectors are less likely to exhibit genotoxic behavior and monitor if these vectors activate proto-oncogenes (genes that may lead to cancer).

Key Points: 
  • These assays enable preclinical risk assessment of gene therapy vectors, potentially paving the way for safer gene therapy vectors used in clinical trials.
  • Combining these assays helps assess vector genotoxicity risk early in preclinical development and further reaffirms that not all lentiviral vectors are designed the same.
  • In its research, AVROBIO used the two assays in combination to determine the potential genotoxicity risk of six lentiviral vectors.
  • Machine learning algorithms developed from transcriptional data of known genotoxic vectors are used to estimate the transformational potential of candidate vectors.

Bionano Genomics Announces Publication of Study from Sorbonne Université Showing that WGS Identified only 63% of Structural Variations that OGM Detected in Liver Cancer

Retrieved on: 
Tuesday, October 4, 2022
Solution, OGM, GLOBE, Doctor of Philosophy, Complementarity, Liver cancer, Biology, Workflow, Software, Genome, Nasdaq, Disease, Research, Private Securities Litigation Reform Act, Squamous cell carcinoma, Genomics, U.S. Securities and Exchange Commission, Cancer research, Sorbonne, Adoption, HCC, COVID-19, Annual report, Lineagen, SVS, Medicine, Autism, Oncogene, Whole genome sequencing, Hepatocellular carcinoma, WGS, Method, SAN, Security (finance), Tic, Patient, Forward-looking statement, Hospital Insurance and Diagnostic Services Act, Company, Medical imaging, Risk management

The workflow also allowed researchers to compare OGM to WGS, and they reported that, in this study, of all SVs detected using OGM, only 63% were also detected by WGS.

Key Points: 
  • The workflow also allowed researchers to compare OGM to WGS, and they reported that, in this study, of all SVs detected using OGM, only 63% were also detected by WGS.
  • OGM revealed a median of 1.4 times more SVs than WGS, ranging from classical tandem duplications to complex tumor initiating cells (TICs) with multiple template-switching events.
  • Cancer is often thought of as a disease of structural variation, and this study illustrates how OGM has the potential to help unravel the complex mechanisms involved in oncogenesis.
  • The Companys mission is to transform the way the world seesthe genome through OGM solutions, diagnostic services and software.

DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY

Retrieved on: 
Monday, October 3, 2022
Chronic myelomonocytic leukemia, Association, Translational research, CLL, Lymphoma, TET2, RHOA, JCA, Research, Myelodysplastic syndrome, Disease, Lymphatic system, SF, AML, Infection, Chronic lymphocytic leukemia, Japanese Cancer Association, CHF, Acute myeloid leukemia, Medicine, Oncogene, Dasatinib, Safety, RNA, Patient, General Medicine Faculty of RostGMU (Rostov State Medical University), IDH, Isocitrate dehydrogenase, MDS, University, CMML, Pharmaceutical industry, Debiopharm

LAUSANNE, Switzerland , Oct. 3, 2022 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categories: Innovative and/or Disruptive Research – Dr. Akihide Yoshimi and for Translational Research – Prof. Mamiko Sakata-Yanagimoto. The winners were honored with trophies and a monetary prize during the live event of the 81st Annual Meeting of the Japanese Cancer Association (JCA) on Saturday, October 1st in Yokohama, Japan by Prof. Hideyuki Saya President of the JCA and Thierry Mauvernay, President of Debiopharm, and Bertrand Ducrey CEO of Debiopharm. 

Key Points: 
  • "The previous winners of the Mauvernay Award have immediately becomevery well-known scientists in our country, becoming professors and leaders in significant institutes.
  • Therefore, I would say that the Mauvernay Award is definitely a huge step for young cancer research scientists in our country."
  • Dr. Akihide Yoshimi's disruptive research at the National Cancer Center Research Institute, is aimed at understanding and targeting aberrant RNA splicing inhematological malignancies.
  • Since 2005, the Japanese Cancer Association (JCA) and Debiopharm have co-organized the 'JCA-Mauvernay Award'.

SOPHiA GENETICS Unveils Strategy to Drive Health Care Innovations at Inaugural Investor Day Event

Retrieved on: 
Wednesday, September 21, 2022
Sophia, Therapy, Acceleration, Algorithm, Investor relations, Twitter, Machine learning, Entrepreneurship, Research, Neoplasm, U.S. Securities and Exchange Commission, Oncogene, LinkedIn, Sophia Genetics, Company, Health, ECHO, Partnership, Immunotherapy, IVD, Forward-looking statement, Patient, Intelligence, Memorial Sloan Kettering Cancer Center, Cancer, CEO, Arbutus Biopharma, Technology, Instagram, Solution, Rolling circle replication, Drug development, MSK, GENETICS, DNA, Hospital, Multimedia, Precision medicine, Mobile phone, Medical device, Management, Medical imaging, Facebook

BOSTON and GENEVA, Sept. 21, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, hosted its first-ever Investor Day on Tuesday, September 20, 2022, in New York City.

Key Points: 
  • One takeaway from the event was SOPHiA GENETICS' acceleration into the Biopharma space, which opens the door for new opportunities for market growth.
  • SOPHiA GENETICS recently announced a memorandum of understanding to enter into a collaboration with Memorial Sloan Kettering Cancer Center ("MSK").
  • The collaboration agreements will also allow SOPHiA GENETICS' global network of healthcare providers access to MSK's proprietary tumor sequencing tests such as MSK-IMPACT , for analyzing tumors.
  • "Our vision is to expand access to world-class data, including to our current network, which contributes to the collective intelligence of the SOPHiA GENETICS platform," said Philippe Menu, M.D.-Ph.D., Chief Medical Officer, SOPHiA GENETICS.

SOPHiA GENETICS Unveils Strategy to Drive Health Care Innovations at Inaugural Investor Day Event

Retrieved on: 
Wednesday, September 21, 2022
Sophia, Therapy, Acceleration, Algorithm, Investor relations, Twitter, Machine learning, Entrepreneurship, Research, Neoplasm, U.S. Securities and Exchange Commission, Oncogene, LinkedIn, Sophia Genetics, Health, ECHO, Partnership, Immunotherapy, IVD, Forward-looking statement, Vision, Intelligence, Memorial Sloan Kettering Cancer Center, Patient, Cancer, CEO, Technology, Instagram, Boundless, Solution, Sutro Biopharma, Rolling circle replication, Drug development, GENETICS, DNA, GLOBE, Hospital, Precision medicine, Mobile phone, Medical device, Medical imaging, Facebook

BOSTON and GENEVA, Switzerland, Sept. 21, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, hosted its first-ever Investor Day on Tuesday, September 20, 2022, in New York City.

Key Points: 
  • One takeaway from the event was SOPHiA GENETICS acceleration into the Biopharma space, which opens the door for new opportunities for market growth.
  • SOPHiA GENETICS recently announced a memorandum of understanding to enter into a collaboration with Memorial Sloan Kettering Cancer Center (MSK).
  • The collaboration agreements will also allow SOPHiA GENETICS global network of healthcare providers access to MSKs proprietary tumor sequencing tests such as MSK-IMPACT , for analyzing tumors.
  • Our vision is to expand access to world-class data, including to our current network, which contributes to the collective intelligence of the SOPHiA GENETICS platform, said Philippe Menu, M.D.-Ph.D., Chief Medical Officer, SOPHiA GENETICS.

TransCode Therapeutics Appoints MicroRNA Pioneer, Dr. Frank Slack, to its Advisory Board

Retrieved on: 
Thursday, September 8, 2022
COVID-19, Breast, Technology, Research, U.S. Securities and Exchange Commission, Genome, GLOBE, Company, Glioblastoma, Risk, Bachelor of Science, PD-L1, Transcoding, Cancer, Oncogene, Beth Israel Deaconess Medical Center, Molecular biology, Department, Nasdaq, RAS, Diabetes, Drug discovery, Intellectual property, Harvard Medical School, Security (finance), RNA, Tumor microenvironment, Therapy, Tufts University School of Medicine, Ageing, Entrepreneurship, LIN28, Recurrence, Patent, CRISPR, Neoplasm, University of Cape Town, Private Securities Litigation Reform Act, CTO, TTX, Someren-Eind, University, MYC, Doctor of Philosophy, Coronavirus, MicroRNA, Single-nucleotide polymorphism, Annual report, Eye, Pharmaceutical industry, Vaccine

BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the appointment of Frank J.

Key Points: 
  • BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the appointment of Frank J.
  • Slack is one of the most preeminent scientists in the field of small noncoding RNA, commented Zdravka Medarova, PhD , Co-Founder and CTO of TransCode.
  • Slack to our advisory board, commented Michael Dudley , President and Chief Executive Officer of TransCode.
  • TransCode is an RNA oncology company created on the belief that cancer can be effectively treated using RNA therapeutics.